House Committee Takes on Pricing, Patents for Top-Selling Drug Humira

AbbVie Inc.'s (ABBV) pricing practices for some of its top-selling medicines are expected to face fresh scrutiny from federal lawmakers Tuesday, the latest effort by members of Congress probing the cost of prescription drugs.

Democratic members of the U.S. House Committee on Oversight and Reform have been investigating how AbbVie (ABBV) sets the prices of some of its products, including its top-selling immunology drug, Humira.

At a hearing, the committee is scheduled to question AbbVie (ABBV) Chief Executive Richard Gonzalez.

He is expected to face questions about price increases for Humira as well as AbbVie's (ABBV) patents and other efforts to protect the drug from competition from lower-priced copies known as biosimilars.

The company "seeks to overwhelm potential competitors with the sheer number of patents on Humira regardless of whether individual patents were properly granted under U.S. law," committee Democrats wrote in a report released before the hearing. "If one patent is invalidated, AbbVie (ABBV) has another patent waiting."

AbbVie (ABBV) declined to comment, a spokesman said.

Republican members of the committee don't plan to issue a report related to the hearing before its start, a spokeswoman for them said.

Patents on Covid-19 vaccines have emerged as an issue in the coronavirus pandemic, as some governments push for intellectual property rights to be temporarily waived to spur additional production.

The Biden administration recently lent its support for temporarily waiving the vaccine patents.

Humira, which treats a range of immune conditions including rheumatoid arthritis and gut disorders, is the top- selling drug in the U.S. with more than $16.1 billion in sales last year.

AbbVie (ABBV) has raised Humira's price 27 times since it launched in 2003, with a year's supply now costing $77,586 before insurance and rebates, according to the report by committee Democrats.

Humira's current price is 470% higher than from when the drug launched in 2003, according to the report.

The initial U.S. patent for Humira expired in December 2016, but the company has been taking out additional patents covering its formulation and manufacturing, among other things.

AbbVie (ABBV) executives in 2014 forecast Humira biosimilars would arrive in the U.S. in 2017 and decrease sales by $1.5 billion that year, according to the report, citing company documents.

The drugmaker, based in the suburbs of Chicago, has obtained or applied for at least 257 Humira patents, 90% of which were filed after the drug was launched, according to the report.

The company obtained eight patents under a law designed by Congress to encourage development of drugs for rare diseases affecting fewer than 200,000 people in the U.S., according to the report.

In one instance, AbbVie (ABBV) split the patient population of a rare skin condition into two, a general one and one for patients at least 12 years old. The maneuvers extended Humira's patent protection beyond the seven years intended by the federal orphan-drug law, according to the report.

AbbVie (ABBV) viewed the U.S. patent system as more permissive than other countries' intellectual-property systems, the Democrats on the committee said, citing company documents.

Europe's patent system precluded many patents obtained in the U.S., according to one of the company documents, an AbbVie (ABBV) white paper, that the committee Democrats cited. In Europe, several biosimilars to Humira have been available since 2018 at a reduced price.

The first lower-priced alternatives to Humira, known as biosimilars, aren't scheduled to hit the U.S. market until 2023.

AbbVie (ABBV) staved off biosimilar competition by reaching deals with companies that agreed to delay launches of their lower-priced copies, according to the report and the companies.

Some of these biosimilars have been approved for several years. A biosimilar from Amgen Inc., which is scheduled to launch in 2023 under an agreement with AbbVie (ABBV), was approved by regulators in 2016.

Write to Jared S. Hopkins at

  (END) Dow Jones Newswires
  05-18-21 1003ET
  Copyright (c) 2021 Dow Jones & Company, Inc.

News, commentary and research reports are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.